Abstract 5340
Background
HGSOC is known to demonstrate diverse molecular heterogeneity. It is unclear whether the tumor microenvironments such as the stromal components in the extracellular matrix (ECM) also exist heterogeneity.
Methods
As a proof-of concept study, characterization of collagen patterns was performed on 60 unstained formalin-fixed paraffin embedded (FFPE) HGSOC samples (three sections from each of the 20 patients). Each section with 5 micron thickness and a minimum tumour surface area of 40 mm2 were scanned by using a multiphoton imaging system (Genesis 200, HistoIndex) following deparaffinization. Parameters including Collagen Area Ratio (CAR), Collagen Fiber Density (CFD), Collagen Reticulation Index (CRI), Collagen Fiber Number (CFN), Collagen Fiber Thickness (CFT), and Collagen Fiber Length (CFL) were analysed. Unsupervised hierarchical clustering analysis was performed.
Results
Unsupervised hierarchical clustering of the collagen parameters revealed four distinct patterns in HGSOC samples. G1 tumors consisted of long and thick collagen fibers with high CFT and CFL. G2 tumors were low in all the collagen parameters, suggesting a relatively “clean” stromal without collagen deposition. G3 tumors consisted of dense collagen fibers with high CRI suggestive of extensive cross alignment among the fibers. G4 tumors were high in CFN and low in CRI, CFT and CFL, suggesting a stroma loaded with high amount of thin and short collagen fibers without cross alignment.The collagen patterns were not exclusive for specific organ sites (ovary, fallopian tube, other metastatic sites) except that the collagen pattern from the omental metastases were mainly G2 (10/18; 55.6%) and G4 (6/18; 33.3%).
Conclusions
The stromal component in the ECM of HGSOC can be successfully quantitated by the multi-photon imaging technology on unstained FFPE sections. The collagen component exhibited significant heterogeneity in terms of the number, thickness, length, and reticulation patterns. The contribution of different collagen patterns to clinical outcomes and the correlation with known molecular subtypes in HGSOC warrants further investigation in larger cohorts.
Clinical trial identification
Editorial acknowledgement
Legal entity responsible for the study
National University of Singapore.
Funding
National Medical Research Council of Singapore.
Disclosure
All authors have declared no conflicts of interest.
Resources from the same session
5465 - Proof of concept clinical study by US-guided intratumor injection of VCN-01, an oncolytic adenovirus expressing hyaluronidase in patients with pancreatic cancer
Presenter: Manuel Hidalgo
Session: Poster Display session 1
Resources:
Abstract
2555 - A Phase 1a/b first-in-human, open-label, dose-escalation, safety, PK and PD study of TP-0903 in solid tumors
Presenter: John Sarantopoulos
Session: Poster Display session 1
Resources:
Abstract
3533 - First in human phase 1/2a study of PEN-866, a Heat Shock Protein 90 (HSP90) ligand – SN38 conjugate for patients with advanced solid tumors: Phase 1 results
Presenter: Johanna Bendell
Session: Poster Display session 1
Resources:
Abstract
4114 - A Phase I Open-Label, Non-Randomized Study of Recombinant Super-Compound Interferon (rSIFN-co) In Patients with Advanced Solid Tumors
Presenter: Amanda Seet
Session: Poster Display session 1
Resources:
Abstract
2537 - Evaluation of Pharmacodynamic (PD) Biomarkers in Advanced Cancer Patients Treated with Oxidative Phosphorylation (OXPHOS) Inhibitor, OPC-317 (OPC)
Presenter: Jie Qing Eu
Session: Poster Display session 1
Resources:
Abstract
5764 - Pharmacokinetic (PK) assessment of BT1718: A phase 1/2a study of BT1718, a first in class Bicycle Toxin Conjugate (BTC), in patients (pts) with advanced solid tumours
Presenter: Natalie Cook
Session: Poster Display session 1
Resources:
Abstract
2683 - A phase I open label dose escalation trial evaluating VT1021 in patients with advanced solid tumors.
Presenter: Wael Harb
Session: Poster Display session 1
Resources:
Abstract
3609 - Interim Results from Trial of SL-801, a Novel XPO-1 Inhibitor, in Patients with Advanced Solid Tumors
Presenter: Judy Wang
Session: Poster Display session 1
Resources:
Abstract
3485 - Phase 1 Trial of Fruquintinib in Patients with Advanced Solid Tumors: Results of the Dose Escalation Phase
Presenter: Andrea Wang-Gillam
Session: Poster Display session 1
Resources:
Abstract
4085 - A Phase 1, Open-Label, Dose-Escalation Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Antitumor Activity of ADCT-601 in Patients with Advanced Solid Tumors
Presenter: Anthony Tolcher
Session: Poster Display session 1
Resources:
Abstract